Related Experiment Video
Updated: Jul 10, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
Insulin administration may trigger pancreatic beta-cell destruction in patients with type 2 diabetes
Mai Nakamura1, Wataru Nishida, Yuya Yamada
1Department of Molecular and Genetic Medicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime 791-0295, Japan.
Abstract:
Insulin administration causes various types of immune response to insulin. However, there have been no reports that insulin administration triggers pancreatic beta-cell destruction in diabetic patients. We evaluated three patients who had suffered from type 2 diabetes or impaired glucose tolerance for 5-30 years. After an episode of diabetic mononeuropathy or poor glycemic control, they started human insulin therapy. All the patients' serum or urinary C-peptide levels were preserved before insulin therapy, whereas within a few months they rapidly declined to below detection limits. A high titer of insulin antibody was detected at or after the development of insulin deficiency. Shortly after the initiation of insulin therapy, two of the patients developed an insulin allergy. Autoantibodies to GAD65 or IA-2 were negative throughout the clinical course in two cases, but transiently positive in one case. In a histological examination of pancreas tissue obtained by a pancreatic biopsy in one case, mononuclear cell infiltration into the islets was observed. They all had a type 1 diabetes high-risk HLA class II haplotype in Japanese, and class I alleles of the insulin gene VNTR. The above findings suggest that insulin administration may have triggered pancreatic beta-cell destruction in these patients.
Insights
Human insulin therapy may trigger pancreatic beta-cell destruction in patients with type 2 diabetes. This immune response led to rapid insulin deficiency and was associated with insulin antibodies and allergies.
Area of Science:
- Immunology
- Endocrinology
- Diabetology
Background:
- Insulin therapy is common for diabetes management.
- Immune responses to insulin are known but typically do not involve beta-cell destruction.
- Previous literature lacks reports of insulin triggering pancreatic beta-cell destruction in diabetic patients.
Observation:
- Three patients with long-standing type 2 diabetes or impaired glucose tolerance developed rapid C-peptide decline after initiating human insulin therapy.
- These patients exhibited high insulin antibody titers and, in some cases, insulin allergy.
- Histological examination revealed islet mononuclear cell infiltration in one patient.
Findings:
- Human insulin administration appeared to trigger autoimmune pancreatic beta-cell destruction in susceptible individuals.
- The destruction was characterized by a rapid loss of endogenous insulin production (C-peptide).
- Genetic predisposition (HLA class II haplotype, insulin gene VNTR) was noted in the affected patients.
Implications:
- Insulin therapy might induce or exacerbate autoimmune destruction in specific diabetic patient populations.
- This phenomenon could represent a novel mechanism contributing to type 1 diabetes development or progression.
- Further research is needed to identify at-risk individuals and explore preventative strategies.
Related Concept Videos
Type I Diabetes II: Pathophysiology
Type I Diabetes I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Introduction

